CY1106656T1 - Χρηση ελαστασης για διανοιξη αποφραγμενων αρτηριων και φλεβων - Google Patents

Χρηση ελαστασης για διανοιξη αποφραγμενων αρτηριων και φλεβων

Info

Publication number
CY1106656T1
CY1106656T1 CY20071100790T CY071100790T CY1106656T1 CY 1106656 T1 CY1106656 T1 CY 1106656T1 CY 20071100790 T CY20071100790 T CY 20071100790T CY 071100790 T CY071100790 T CY 071100790T CY 1106656 T1 CY1106656 T1 CY 1106656T1
Authority
CY
Cyprus
Prior art keywords
circuit
blockage
clocked
arteries
veins
Prior art date
Application number
CY20071100790T
Other languages
Greek (el)
English (en)
Inventor
Nicholas F. Franano
Original Assignee
Proteon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics, Inc. filed Critical Proteon Therapeutics, Inc.
Publication of CY1106656T1 publication Critical patent/CY1106656T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Processing Of Meat And Fish (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20071100790T 1999-09-24 2007-06-14 Χρηση ελαστασης για διανοιξη αποφραγμενων αρτηριων και φλεβων CY1106656T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15593899P 1999-09-24 1999-09-24
PCT/US2000/026237 WO2001021574A1 (en) 1999-09-24 2000-09-24 Systems and methods for opening obstructed biological conduits

Publications (1)

Publication Number Publication Date
CY1106656T1 true CY1106656T1 (el) 2012-01-25

Family

ID=22557384

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20071100790T CY1106656T1 (el) 1999-09-24 2007-06-14 Χρηση ελαστασης για διανοιξη αποφραγμενων αρτηριων και φλεβων
CY20111100865T CY1112329T1 (el) 1999-09-24 2011-09-08 Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων
CY20151100477T CY1117932T1 (el) 1999-09-24 2015-05-29 Ελασταση για διανοιξη αποφραγμενων βιολογικων διαυλων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20111100865T CY1112329T1 (el) 1999-09-24 2011-09-08 Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων
CY20151100477T CY1117932T1 (el) 1999-09-24 2015-05-29 Ελασταση για διανοιξη αποφραγμενων βιολογικων διαυλων

Country Status (11)

Country Link
EP (4) EP1220830B1 (enExample)
JP (2) JP5763286B2 (enExample)
AT (2) ATE361095T1 (enExample)
AU (1) AU7612100A (enExample)
CA (1) CA2385488C (enExample)
CY (3) CY1106656T1 (enExample)
DE (1) DE60034694T2 (enExample)
DK (3) DK1220830T3 (enExample)
ES (3) ES2534938T3 (enExample)
PT (3) PT1220830E (enExample)
WO (1) WO2001021574A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
WO2004073504A2 (en) * 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
US20090196865A1 (en) * 2004-09-22 2009-08-06 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
EP4772625A2 (en) 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzyme
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
DK3589204T3 (da) 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4803294A (en) * 1987-10-29 1989-02-07 G. D. Searle & Co. Process and intermediates for the preparation of halogenated protease inhibitors
JPH0286777A (ja) * 1988-09-22 1990-03-27 Sankyo Co Ltd サル膵臓エラスターゼｉ
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
ES2072424T3 (es) * 1989-01-27 1995-07-16 Immunolytics Inc Formula y metodo para el tratamiento de hipertrofias prostaticas benignas.
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL8900943A (nl) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V Protease inhibitor.
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
ATE354638T1 (de) * 1994-12-13 2007-03-15 Human Genome Sciences Inc Menschlicher gewebsinhibitor von metalloproteinase-4
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2385488A1 (en) 2001-03-29
DK2363142T3 (en) 2015-04-20
DE60034694T2 (de) 2008-01-17
DE60034694D1 (de) 2007-06-14
EP2363142A9 (en) 2011-10-19
HK1162302A1 (en) 2012-08-31
DK1923068T3 (da) 2011-06-27
CY1117932T1 (el) 2017-05-17
PT2363142E (pt) 2015-08-04
JP2012131830A (ja) 2012-07-12
ATE511854T1 (de) 2011-06-15
ATE361095T1 (de) 2007-05-15
EP1220830A4 (en) 2005-03-30
PT1220830E (pt) 2007-06-11
EP1923068B1 (en) 2011-06-08
CY1112329T1 (el) 2015-12-09
EP2363142A1 (en) 2011-09-07
EP2363142B1 (en) 2015-03-25
EP1220830A1 (en) 2002-07-10
EP2363142B8 (en) 2015-06-10
ES2284528T3 (es) 2007-11-16
WO2001021574A1 (en) 2001-03-29
ES2534938T3 (es) 2015-04-30
AU7612100A (en) 2001-04-24
ES2364191T3 (es) 2011-08-26
CA2385488C (en) 2015-07-07
JP5763286B2 (ja) 2015-08-12
PT1923068E (pt) 2011-07-29
DK1220830T3 (da) 2007-07-16
EP1220830B1 (en) 2007-05-02
JP5793461B2 (ja) 2015-10-14
JP2003523319A (ja) 2003-08-05
WO2001021574A9 (en) 2002-12-27
EP2332568A1 (en) 2011-06-15
EP1923068A1 (en) 2008-05-21

Similar Documents

Publication Publication Date Title
DK1626714T3 (da) Dirarylurinstoffer mod sygdomme medieret af PDGFR
DK0717635T3 (da) Fremgangsmåder til reduktion af gastrointestinal motilitet
DE69417232D1 (de) Intravaginales wirkstoffabgabesystem
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
CY1117932T1 (el) Ελασταση για διανοιξη αποφραγμενων βιολογικων διαυλων
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
EA200000445A1 (ru) Способы лечения состояния гиперкоагуляции или приобретенной недостаточности белка c
ES2094716T3 (es) Formula infantil antirregurgitacion.
WO2000018331A3 (en) Drug delivery systems
EA200300560A1 (ru) Улучшенный способ лечения
ZA200403803B (en) Selective targeting of apoptotic cells.
BR0010314B1 (pt) solução aquosa de conservação de tecidos e órgãos.
AU3527700A (en) Foam control agents for silicone surfactants
SE0004710L (sv) System och förfarande
ATE308973T1 (de) Heparin-stent
DK0637327T3 (da) Polyetheramidoaminhydrogeler som hepariniserbare materialer
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
UA61133C2 (uk) Офтальмологічний розчин, корисний як штучні сльози, що містить глікоген
PL354961A1 (en) Prevention and treatment of diseases associated with blood coagulation
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
ES2103482T3 (es) Antigeno de linfocitos t citotoxicos utilizado como inhibidor de la cisteina proteasa.
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
GT199900039A (es) Combinaciones de estatina-inhibidor de mmp.
WO2001096398A3 (en) Uncoupling proteins as targets for the treatment of heart failure